AN2 Therapeutics, Inc. 8-K

What Happened
AN2 Therapeutics, Inc. (ANTX) announced in an 8‑K that on March 19, 2026 the Board approved a repricing of all outstanding stock options granted under its 2017 and 2022 equity incentive plans. The exercise price for each eligible option was reduced to $3.91 per share (the closing price on March 19, 2026). Eligible options include awards held by named executive officers and non‑employee directors; all other terms of the options remain unchanged.

Key Details

• Repricing effective date: March 19, 2026.
• New exercise price for all Eligible Options: $3.91 per share.
• “Premium End Date” (the earliest of): (i) September 19, 2027; (ii) a change in control; or (iii) the holder’s death or disability.
• If an Eligible Option is exercised or the holder’s service ends prior to the Premium End Date, the holder must pay the original exercise price per share.
• Aggregate Eligible Options held by named executives: Eric Easom (CEO/Board chair) — 742,649 options (original prices $6.60–$17.28); Joshua Eizen (CLO/COO) — 142,150 options (original prices $14.29–$17.88); Lucy Day (CFO) — 221,965 options (original prices $6.60–$17.28).

Why It Matters
This action materially changes the strike price of the company’s outstanding options, directly affecting the economics of executive and employee equity awards. The Board says the repricing is intended to retain and motivate participants while avoiding substantial new equity grants (dilution) or additional cash compensation. Investors should note the special Premium End Date rule requiring original exercise prices if options are exercised or service ends before that date, and track any future disclosures about option exercises, potential dilution, or related accounting impacts.